Siegel DS, Schiller GJ, Song KW, et al. - Whether pomalidomide plus low-dose dexamethasone affords a safe and effective treatment option when administered immediately following lenalidomide-based treatment failure in patients with relapsed/refractory multiple myeloma (RRMM) and two previous lines of therapy, was investigated in cohort A of the phase 2 MM-014 trial. Researchers administered pomalidomide 4 mg on days 1 to 21 of 28-day cycles, and dexamethasone 40 mg (20 mg for patients aged > 75 years) on days 1, 8, 15 and 22 of 28-day cycles. The overall response rate was estimated to be 32·1% (28·2% in the prior-bortezomib subgroup). The estimated median progression-free survival and median overall survival were 12·2 months and 41·7 months, respectively. Anaemia (25·0%), pneumonia (14·3%) and fatigue (14·3%) were documented as the most commonly experienced grade 3/4 treatment-emergent adverse events. In lenalidomide-pretreated patients with RRMM, including those who have become refractory to lenalidomide, earlier sequencing of pomalidomide-based therapy was supported based on these findings.